156 related articles for article (PubMed ID: 18495540)
1. Expansion of CD56- NK cells in chronic HCV/HIV-1 co-infection: reversion by antiviral treatment with pegylated IFNalpha and ribavirin.
Gonzalez VD; Falconer K; Michaëlsson J; Moll M; Reichard O; Alaeus A; Sandberg JK
Clin Immunol; 2008 Jul; 128(1):46-56. PubMed ID: 18495540
[TBL] [Abstract][Full Text] [Related]
2. Interferon-alpha-induced TRAIL on natural killer cells is associated with control of hepatitis C virus infection.
Stegmann KA; Björkström NK; Veber H; Ciesek S; Riese P; Wiegand J; Hadem J; Suneetha PV; Jaroszewicz J; Wang C; Schlaphoff V; Fytili P; Cornberg M; Manns MP; Geffers R; Pietschmann T; Guzmán CA; Ljunggren HG; Wedemeyer H
Gastroenterology; 2010 May; 138(5):1885-97. PubMed ID: 20334827
[TBL] [Abstract][Full Text] [Related]
3. Increased proportion of the CD56(bright) NK cell subset in patients chronically infected with hepatitis C virus (HCV) receiving interferon-alpha and ribavirin therapy.
Lee S; Watson MW; Flexman JP; Cheng W; Hammond T; Price P
J Med Virol; 2010 Apr; 82(4):568-74. PubMed ID: 20166183
[TBL] [Abstract][Full Text] [Related]
4. Expansion of functionally skewed CD56-negative NK cells in chronic hepatitis C virus infection: correlation with outcome of pegylated IFN-alpha and ribavirin treatment.
Gonzalez VD; Falconer K; Björkström NK; Blom KG; Weiland O; Ljunggren HG; Alaeus A; Sandberg JK
J Immunol; 2009 Nov; 183(10):6612-8. PubMed ID: 19846870
[TBL] [Abstract][Full Text] [Related]
5. Increased CD56(bright) NK cells in HIV-HCV co-infection and HCV mono-infection are associated with distinctive alterations of their phenotype.
Bhardwaj S; Ahmad F; Wedemeyer H; Cornberg M; Schulze Zur Wiesch J; van Lunzen J; Sarin SK; Schmidt RE; Meyer-Olson D
Virol J; 2016 Apr; 13():67. PubMed ID: 27091211
[TBL] [Abstract][Full Text] [Related]
6. Chronic hepatitis C viral infection reduces NK cell frequency and suppresses cytokine secretion: Reversion by anti-viral treatment.
Dessouki O; Kamiya Y; Nagahama H; Tanaka M; Suzu S; Sasaki Y; Okada S
Biochem Biophys Res Commun; 2010 Mar; 393(2):331-7. PubMed ID: 20138830
[TBL] [Abstract][Full Text] [Related]
7. CD56(+dim) and CD56(+bright) cell activation and apoptosis in hepatitis C virus infection.
Lin AW; Gonzalez SA; Cunningham-Rundles S; Dorante G; Marshall S; Tignor A; Ha C; Jacobson IM; Talal AH
Clin Exp Immunol; 2004 Aug; 137(2):408-16. PubMed ID: 15270860
[TBL] [Abstract][Full Text] [Related]
8. Activating NK cell receptor expression/function (NKp30, NKp46, DNAM-1) during chronic viraemic HCV infection is associated with the outcome of combined treatment.
Bozzano F; Picciotto A; Costa P; Marras F; Fazio V; Hirsch I; Olive D; Moretta L; De Maria A
Eur J Immunol; 2011 Oct; 41(10):2905-14. PubMed ID: 21695691
[TBL] [Abstract][Full Text] [Related]
9. T cell receptor excision circles (TRECs), CD4+, CD8+, and their CD45RO+, and CD45RA+, subpopulations in hepatitis C virus (HCV)-HIV-co-infected patients during treatment with interferon alpha plus ribavirin: analysis in a population on effective antiretroviral therapy.
Arizcorreta A; Márquez M; Fernández-Gutiérrez C; Guzmán EP; Brun F; Rodríguez-Iglesias M; Girón-González JA
Clin Exp Immunol; 2006 Nov; 146(2):270-7. PubMed ID: 17034579
[TBL] [Abstract][Full Text] [Related]
10. [Alteration of CD100 expression on natural killer cells in chronic patients with hepatitis C virus before and after initiation of antiviral treatment].
He Y; Li B; Zhou Y; Zhang Y; Guo Y; Ji G; Fan C; Jia Z
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2014 Aug; 30(8):856-60. PubMed ID: 25108441
[TBL] [Abstract][Full Text] [Related]
11. CD56
Judge CJ; Kostadinova L; Sherman KE; Butt AA; Falck-Ytter Y; Funderburg NT; Landay AL; Lederman MM; Sieg SF; Sandberg JK; Anthony DD
J Leukoc Biol; 2017 Jul; 102(1):171-184. PubMed ID: 28400540
[TBL] [Abstract][Full Text] [Related]
12. Natural killer cell dynamic profile is associated with treatment outcome in patients with chronic HCV infection.
Oliviero B; Mele D; Degasperi E; Aghemo A; Cremonesi E; Rumi MG; Tinelli C; Varchetta S; Mantovani S; Colombo M; Mondelli MU
J Hepatol; 2013 Jul; 59(1):38-44. PubMed ID: 23499727
[TBL] [Abstract][Full Text] [Related]
13. Chronic immune activation in the T cell compartment of HCV/HIV-1 co-infected patients.
Sandberg JK; Falconer K; Gonzalez VD
Virulence; 2010; 1(3):177-9. PubMed ID: 21178437
[TBL] [Abstract][Full Text] [Related]
14. Natural killer cell immunodeficiency in HIV disease is manifest by profoundly decreased numbers of CD16+CD56+ cells and expansion of a population of CD16dimCD56- cells with low lytic activity.
Hu PF; Hultin LE; Hultin P; Hausner MA; Hirji K; Jewett A; Bonavida B; Detels R; Giorgi JV
J Acquir Immune Defic Syndr Hum Retrovirol; 1995 Nov; 10(3):331-40. PubMed ID: 7552495
[TBL] [Abstract][Full Text] [Related]
15. Natural killer cell activity and function in chronic HCV-infected patients during peg interferon and ribavirin: early effects of active substance use.
Hotho DM; Kreefft K; Groothuismink ZM; Janssen HL; de Knegt RJ; Boonstra A
Antiviral Res; 2013 Mar; 97(3):347-55. PubMed ID: 23291200
[TBL] [Abstract][Full Text] [Related]
16. Treatment of chronic hepatitis C in human immunodeficiency virus/hepatitis C virus-coinfected patients in the era of pegylated interferon and ribavirin.
Bräu N
Semin Liver Dis; 2005 Feb; 25(1):33-51. PubMed ID: 15731996
[TBL] [Abstract][Full Text] [Related]
17. Association of NKG2A with treatment for chronic hepatitis C virus infection.
Harrison RJ; Ettorre A; Little AM; Khakoo SI
Clin Exp Immunol; 2010 Aug; 161(2):306-14. PubMed ID: 20550548
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of interferon in immunocompromised HCV patients after liver transplantation or with HIV co-infection.
Reiberger T; Rasoul-Rockenschaub S; Rieger A; Ferenci P; Gangl A; Peck-Radosavljevic M
Eur J Clin Invest; 2008 Jun; 38(6):421-9. PubMed ID: 18489402
[TBL] [Abstract][Full Text] [Related]
19. Insulin resistance in HCV mono-infected and in HIV/HCV co-infected patients: Looking to the future.
Cammà C; Petta S
J Hepatol; 2009 Apr; 50(4):648-51. PubMed ID: 19231012
[No Abstract] [Full Text] [Related]
20. Safety and efficacy of an induction dose of pegylated interferon alpha-2a on early hepatitis C virus kinetics in HIV/HCV co-infected patients: the CORAL-1 multicentre pilot study.
Tural C; Solà R; Rubio R; Santín M; Planas R; Quereda C; Berenguer J; Montes-Ramírez M; Clotet B;
J Viral Hepat; 2007 Oct; 14(10):704-13. PubMed ID: 17875005
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
